Potential Breakthrough in Cell Reprogramming as OpenAI and Retro Biosciences Report 50x Pluripotency Marker Expression Gains

OpenAI and Retro Biosciences have released new findings from a joint effort in AI-driven protein engineering. Using GPT-4b micro, a …

Continue ›››

Immunai Opens Free Single-Cell Sequencing Program for Academic Labs

Immunai, a New York–based company specializing in AI-driven immune system mapping, has announced a program offering academic researchers free access …

Continue ›››

KYORIN Pharmaceutical Adopts AI Drug Discovery Platform From Elix

KYORIN Pharmaceutical has adopted Elix Discovery, an AI-based drug discovery platform developed by Tokyo-based Elix. The system is designed to …

Continue ›››

Innovatrix and Opyl Partner to Launch AI-Driven Insurance for Clinical Trial Failure

Innovatrix Capital has partnered with Opyl Limited’s TrialKey platform to embed predictive analytics into parametric insurance products designed to cover …

Continue ›››

How AI Is Transforming Medicinal Chemistry Between Discovery and Manufacture

In medicinal chemistry, the “make” stage of the design–make–test–analyze (DMTA) cycle is often where good ideas go to die. Synthetic …

Continue ›››

Ginkgo, Inductive Bio, and Tangible Scientific Connect AI Models with Automated Labs for Drug Discovery

Ginkgo Bioworks’ Datapoints unit, Inductive Bio, and Tangible Scientific have partnered to deliver a lab-in-the-loop workflow that ties AI-driven molecular …

Continue ›››

Silicon Valley’s Molecular Devices Brings AI to Brain Organoid Culture

Molecular Devices has released an upgrade to its CellXpress.ai Automated Cell Culture System, adding rocking incubation and AI-driven workflow automation …

Continue ›››

Owkin to Bring Agentic AI into Vienna’s Oncology Ecosystem

Owkin and the Comprehensive Cancer Center of the Medical University of Vienna have entered a collaboration to deploy agentic AI …

Continue ›››

Generative AI Designs Novel Antibiotics Against MRSA and Drug-Resistant Gonorrhea

Researchers at MIT and the Broad Institute have reported generative artificial intelligence systems capable of designing entirely new antibiotics, including …

Continue ›››

BioAge Labs Begins Phase 1 Trial of Oral NLRP3 Inhibitor for Obesity

BioAge Labs has started human testing of BGE-102, an orally available NLRP3 inhibitor designed to cross the blood-brain barrier. The …

Continue ›››

Kriya Raises $313 Million to Advance Gene Therapy Programs

Kriya Therapeutics has secured $313.3 million in new financing, according to a recent SEC filing. The filing did not outline …

Continue ›››

AI Drug Developer Insilico Medicine Readies Brain-Penetrant Therapy For Parkinson’s Trials

Insilico Medicine reports it has finished IND-enabling work for ISM8969, an oral, blood-brain-barrier-penetrant NLRP3 inhibitor and aims to file an IND in …

Continue ›››